Fate Therapeutics Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company advancing “off-the-shelf” cellular immunotherapies designed to be manufactured in large batches and delivered on demand. The company’s core technology centers on human induced pluripotent stem cells (iPSCs), which are engineered and expanded to create consistent, renewable starting material for immune cell therapies. Using this platform, Fate produces multiplex-engineered T cells and natural killer (NK) cells intended to improve anti-tumor activity, persistence, and functional control compared with conventional approaches.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Fate Therapeutics is focused on pioneering groundbreaking science to address severe, life-threatening diseases with significant unmet needs and limited treatment options. The company's research and development initiatives are centered around the development of first-in-class cellular immunotherapies for cancer and autoimmune diseases. The company is advancing multiple product candidates through clinical development and conducting preclinical research and development activities in other programs. The company is also engaged in collaborations, such as with Ono Pharmaceutical, to research and develop iPSC-derived CAR T-cell and CAR NK cell product candidates for the treatment of solid tumors. Its R&D unit is responsible for the research, preclinical development, process and scale-up development, manufacture, and clinical development of the company's product candidates. The unit also manages the research and development of the company's cell programming technology, including the iPSC product platform, and performs research and development activities under collaboration agreements. The company's pipeline includes several product candidates, such as FT819, FT839, FT522, FT825, FT836, and others targeting various indications in oncology and autoimmune diseases. It incurred research and development expenses of US$107.8 million in FY2025.